Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 7Stomach Neoplasms 3Adenocarcinoma Of Esophagus 3Uveal Melanoma 2Carcinoma, Hepatocellular 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Muscle Invasive Bladder Urothelial Carcinoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hepatitis B 1Gliosarcoma 1GATA2 Deficiency 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced or Metastatic Solid Malignancies 1Adenocarcinoma of Lung 1

Interventions

Temozolomide 2veliparib 1Radiotherapy 1Radiation 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Contrast Media 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Gliosarcoma × Nivolumab × Clear all
NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡